Francisco Silva - 06 Oct 2025 Form 4 Insider Report for BioRestorative Therapies, Inc. (BRTX)

Role
VP of Research and Development, Director
Signature
/s/ Francisco Silva
Issuer symbol
BRTX
Transactions as of
06 Oct 2025
Net transactions value
+$18,750
Form type
4
Filing time
20 Oct 2025, 08:18:15 UTC
Previous filing
19 Feb 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Silva Francisco VP of Research and Development, Director C/O BIORESTORATIVE THERAPIES, INC., 40 MARCUS DRIVE, SUITE ONE, MELVILLE /s/ Francisco Silva 17 Oct 2025 0001527241

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BRTX Comon Stock Award $18,750 +11,719 +7.3% $1.60 171,384 06 Oct 2025 Direct
holding BRTX Common Stock 12,136 06 Oct 2025 IRA

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BRTX Warrant Award $0 +11,719 $0.000000 11,719 06 Oct 2025 Common Stock 11,719 $2.75 Direct
holding BRTX Stock Option 15 06 Oct 2025 Common Stock 15 $3000.00 Direct F1
holding BRTX Stock Option 20 06 Oct 2025 Common Stock 20 $3000.00 Direct F1
holding BRTX Stock Option 25 06 Oct 2025 Common Stock 25 $3000.00 Direct F1
holding BRTX Stock Option 293,479 06 Oct 2025 Common Stock 293,479 $5.08 Direct F1
holding BRTX Stock Option 42,059 06 Oct 2025 Common Stock 42,059 $5.08 Direct F1
holding BRTX Stock Option 106,762 06 Oct 2025 Common Stock 106,762 $2.91 Direct F2
holding BRTX Stock Option 394,737 06 Oct 2025 Common Stock 394,737 $1.45 Direct F3
holding BRTX Stock Option 768,979 06 Oct 2025 Common Stock 768,979 $2.46 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Francisco Silva is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 The option is currently exercisable.
F2 The option vests and becomes exercisable to the extent of 53,381 shares on February 17, 2023 and 53,381 shares in eight nearly equal quarterly installments beginning February 17, 2024 and continuing every three months thereafter until fully vested.
F3 The option vests and becomes exercisable to the extent of 197,369 shares on February 13, 2024 and 197,368 shares in eight nearly equal quarterly installments beginning February 13, 2025 and continuing every three months thereafter until fully vested.
F4 The option vests and becomes exercisable to the extent of 384,490 shares on February 14, 2025 and 384,489 shares in eight nearly equal quarterly installments beginning February 14, 2026 and continuing every three months thereafter until fully vested.